The invention provides a system and method for delivering antibiotic powder to a surgical wound that reduces the likelihood of contamination. A pre-packaged, sterile antibiotic powder delivery system comprises a container; a measured dosage of an antibiotic powder disposed within the container; and a sieve top attached to the top of the container, wherein the container and sieve top are sealed as a unit in a sterile packaging. To use the delivery system in the sterile surgery or operating room environment, the delivery system is removed from the sterile packaging. The delivery system is shaken over the surgical wound for a reasonable amount of time to cover the entire wound, avoid surgeon fatigue at the end of surgery, and avoid prolonging the total time the wound is open.

HealthPartners Research &amp; Education

Antibiotic delivery system and method

This invention is a method of killing the stealthy intra-cellular bacteria which cause many Th1 and `Autoimmune` diseases. The methods described in this invention will treat and prevent the diseases customarily named Diabetes Type 1, Diabetes Type 2, Rheumatic Arthritis, Reactive Arthritis, Osteo Arthritis, Psoriasis, Scleroderma, Osteoporosis, Atherosclerosis, Myocarditis, Endocarditis, Pericarditis, Alzheimer's, Cystic Fibrosis, Hashimoto's Thyroiditis, Graves Disease, Leprosy, Syphilis, Lyme, Chronic Lyme, Borreliosis, Neuro-borreliosis, Inflammatory Bowel Disease (IBD), Tuberculosis, Latent Tuberculosis, Sarcoidosis, Neurosarcoidosis, Lupus, Discoid Lupus, Lupus Pernio, Lupus Nephritis, Systemic Lupus Erythematosis (SLE), Asthma, Macular Degeneration, Uveitis, Crohn's, Irritable Bowel Syndrome, Sjogren's, Fibromyalgia, Chronic Fatigue Syndrom (CFS), Chronic Fatigue Immune Dysfunction Syndrome (CFIDS), Myalgic Encephalitis (ME), Amyotrophic Lateral Sclerosis (ALS), Parkinson's, Multiple Sclerosis, Autism Spectrum Disorder (ASD), Attention Deficit Disorder (ADD), and Attention Deficit Hyperactivity Disorder (ADHD). This invention achieves this by reducing the ability of the stealthy bacteria to produce proteins with their 70S Ribosome. The 30S and 50S subunits of the bacterial ribosome are targeted individually and collectively. Further, this invention reduces the availability of Angiotensin II to the host's Angiotensin receptors, conditioning the immune system to recognize and kill the bacteria. Finally, this invention reduces the availability of Angiotensin II and cytokines to the bacterial pathogens and thus inhibits the ability of their genome to scavenge (from a host patient) the amino acids, and other biochemicals necessary for bacterial survival.

Marshall; Trevor Gordon

Treatment and prevention of Th1 and `autoimmune` diseases effected with antibiotics and/or angiotensin inhibition

A multi-functional self-healing dental composite may intrinsically repair the micro-crack and prevent the crack from propagating to catastrophic failure, thus significantly extending the service life of the restorative material. The self-healing dental composite includes a dental resin matrix, fillers, healing powder, and healing liquid containing micro-capsules distributed throughout the matrix. Each of the micro-capsules have a silica she formed by the hydrolysis condensation of TEOS in the presence of an aqueous solution of a healing liquid. The healing liquid includes a homo-polymers(s) and/or copolymer(s) of carboxylic acid(s). The healing powder particles distributed throughout the resin matrix, and include alumina, silica and other elements. The self-healing may be triggered automatically as a result of micro-cracking, induced by thereto/mechanical fatigue. During the self-healing process, antibacterial agents may be released to provide protection of the composites against cariogenic bacteria. The self-healing dental composites also may improve tooth remineralization, and caries prevention though fluoride release.

ADA Foundation

ADA FOUNDATION

Multi-functional self-healing dental composites, methods of synthesis and methods of use

New methods for diagnosis and treatment of human dormancy syndrome-related sequellae are provided. Human dormancy syndrome (HDS) is characterized by elevated serum ratio of rT3/fT3 compared to a population of normal subjects. HDS includes fibromyalgia, chronic fatigue, cancer, autoimmune disease, obesity and related dormancy conditions. Dormancy and HDS-related sequellae are imposed on humans by infection with lipopolysaccharide (LPS; or endotoxin)-producing organisms, especially those that are intracellular and those that create antigens that stimulate the TLR pathways. In such instances, the elimination or neutralization of the LPS signal along with the infectious source is required to impact the sequellae of HDS. Treatment includes use of novel and non-obvious doses of antibiotics, optionally including agents that decrease the adverse effects of endotoxin.

antibiotic/fatigue

Antibiotic delivery system and method

Treatment and prevention of Th1 and `autoimmune` diseases effected with antibiotics and/or angiotensin inhibition

Multi-functional self-healing dental composites, methods of synthesis and methods of use

Diagnosis and treatment of human dormancy-related sequellae

Diagnosis and treatment of human dormancy-related sequellae

Den mest komplette databasen med medisinske urter støttet av vitenskap